Proton magnetic resonance spectroscopy in Kennedy syndrome

Archives of Neurology

Volumn 56, Issue 12, 1999, Pages 1465-1471

  Karitzhy, Jochen ^a   Block, Wolfgang ^b   Mdlies, Jörg K ^c   Traber, Frank ^c   Sperfeld, Anne ^b   Schild, Hans H ^a   Malier, Peter ^b   Ludolph, Albert C ^c  

^a UNIVERSITY OF ULM   (Germany)

^b UNIVERSITY OF BONN   (Germany)

^c Andreas Bannowsky Ltd   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLINE; CREATINE PHOSPHATE; LACTIC ACID; TRINUCLEOTIDE;

ARTICLE; BRAIN STEM; CLINICAL ARTICLE; CONTROLLED STUDY; ENERGY METABOLISM; HUMAN; KENNEDY DISEASE; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; TRINUCLEOTIDE REPEAT;

EID: 0032735571     PISSN: 00039942     EISSN: None     Source Type: Journal    
DOI: 10.1001/archneur.56.12.1465     Document Type: Article

References (27)

1. La Spada A, Wilson EM, Lubahn DB, Harding AE, Fischbeck KH. Androgen receptor gene mutations in X-linked spinal and bulbar muscular atrophy. Nature. 1991:352:77-79.
2. Kennedy WR, Alter M, Sung JH. Progressive proximal spinal and bulbar muscular atrophy of late onset: a sex-linked recessive trait. Neurology. 1968:18:671 680.
3. Fischbeck KH. Kennedy disease. J Inherit Metab Dis. 1997:20:152-158.
4. Burke JR, Enghild JJ, Martin ME, et al. Huntingtin and DRPLA proteins selectively interact with the enzyme GADPH. Nature Med. 1996:2:347-350.
5. Koshy B, Matilla T, Burright EN, et al. Spinocerebellar ataxia type-1 and spinobulbar muscular atrophy gene products interact with glyceraldehyde-3-phosphate dehydrogenase. Hum Mol Genet. 1996:5:1311-1318.
6. Harms L, Meierkord H, Timm G, Pfeiffer L, Ludolph AC. Decreased N-acetylaspartate/choline ratio and increased lactate in the frontal lobe of patients with Huntington's disease: a proton magnetic resonance spectroscopy study. JNeurol fJeurosurg Psychiatry. 1997:62:27-30.
7. Koroshetz WJ, Jenkins BG, Rosen BR, Béai MF. Energy metabolism defects in Huntington's disease and effects of coenzyme Q,0. Ann Neurol. 1997:41:160165.
8. Block W, Karitzky J, Traber F, et al. Proton magnetic resonance spectroscopy of the primary motor cortex in patients with motor neuron disease: subgroup analysis and follow-up measurements. Arch Neurol. 1998:55:931 -936.
9. Cwik VA, Hanstock CC, Allen PS, Martin WRW. Estimation of brainstem neuronal loss in amyotrophic lateral sclerosis with in vivo proton magnetic resonance spectroscopy. Neurology. 1998:50:72-77.
10. Simmons ML, Frondoza CG, Coyle JT. Immunocytochemical localization of Nacetyl-aspartate with monoclonal antibodies. Neurosdence. 1991:45:37-45.
11. Urenjak J, Williams SR, Gadian DG, Noble M. Proton nuclear magnetic resonance spectroscopy unambiguously identifies different neural cell types. JNeurosci. 1993:13:981-989.
12. Pavlakis SG, Kingsley PB, Kaplan GP, Stacpole PW, O'Shea M, Lustbader D. Magnetic resonance spectroscopy: use in monitoring MELAS treatment. Arch Neurol. 1998:55:849-852.
13. Nagashima T, Seko K, Hirose K, et al. Familial bulbo-spinal muscular atrophy associated v/ith testicular atrophy and sensory neuropathy (Kennedy-AlterSung syndrome): autopsy case report of two brothers. J Neurol Sei. 1988:87: 141-152.
14. Sobue G, Hashizume Y, Makai E, Hirayama M, Mitsuma T, Takahashi A. X-linked recessive bulbospinal neuronopathy: a clinicopathological study. Brain. 1989: 112:209-232.
15. Li M, Miwa S, Kobayashi Y, et al. Nuclear inclusions of the androgen receptor protein in spinal and bulbar muscular atrophy. Ann Neurol. 1998:44:249-254.
16. Shaw PJ, Thagesen H, Tomkins J, et al. Kennedy's disease: unusual molecular pathologic and clinical features. Neurology. 1998:51:252-255.
17. Masaharu M, Kakimoto Y, Sorimachi M. A gas Chromatographie method for the determination of N-acetyl-aspartic acid, N-acetyl-aspartylglutamic acid and citrylL-glutamic acid and their distributions in the brain and other organs of various species of animals. JNeurochem. 1981:36:804-810.
18. Koller KJ, Zaczek R, Coyle JT. N-acetyl-aspartyl-glutamate: regional levels in rat brain and the effect of brain lesions as determined by a new HPLC method. J Neurochem. 1984:43:1136-1142.
19. Meyerhoff DJ, MacKay S, Constans JM, et al. Axonal injury and membrane alterations in Alzheimer's disease suggested by in vivo proton magnetic resonance spectroscopic imaging. Ann Neurol. 1994:36:40-47.
20. Paulson GW, Liss L, Sweeney PJ. Late onset spinal mucle atrophy: a sex-linked variant of Kugelberg-Welander. Acta Neurol Scand. 1980:61:49-55.
21. Furtado S, Sucherowsky 0, Rewcastle B, Graham L, Klimek ML, Garber A. Relationship between trinucleotide repeats and neuropathological changes in Huntington's disease. Ann Neurol. 1996:39:132-136.
22. Penney JB, Vonsattel JP, MacDonald ME, Gusella JF, Myers RH. CAG repeat number governs the development rate of pathology in Huntington's disease. Ann Neurol. 1997:41:689-692.
23. 11CIRaclopride-PET studies of the Huntington's disease rate of progression: relevance of the trinucleotide repeat length. Ann Neurol. 1998:43:253-255.
24. Doyu M, Sobue G, Mukai E, et al. Severity of X-linked recessive bulbospinal neuronopathy correlates with size of the tandem CAG repeat in androgen receptor gene. Ann Neurol. 1992:32:707-710.
25. Igarashi S, Tanno Y, Onodera 0, et al. Strong correlation between the number of CAG repeats in androgen receptor genes and the clinical onset of features of spinal and bulbar muscular atrophy. Neurology. 1992:42:2300-2302.
26. Amato AA, Prior TW, Barohn RJ, Snyder BS, Papp A, Mendell JR. Kennedy's disease: a clinicopathologic correlation with mutations in the androgen receptor gene. Neurology. 1993;43:791 -794.
27. Shimada N, Sobue G, Doyu M, et al. X-linked recessive bulbospinal neuronopathy: clinical phenotypes and CAG repeat size in the androgen receptor gene. Muscle Nerve. 1995:18:1378-1384.